Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
Mohamed Hussein(Cairo University), Ahmed Mady(University of Toronto), Shmeylan Al Harbi(King Saud bin Abdulaziz University for Health Sciences), Fahad Al-Hameed, Jesna Jose(King Saud bin Abdulaziz University for Health Sciences), Yaseen M. Arabi(World Health Organization), Ghaleb A. Al Mekhlafi(Riyadh Armed Forces Hospital), Wail Bajhmom(King Saud bin Abdulaziz University for Health Sciences), Fatehi Elzein(Riyadh Armed Forces Hospital), Ziad A. Memish(Alfaisal University), Ahmad Deeb(King Saud bin Abdulaziz University for Health Sciences), Abdullah Almotairi(King Faisal Specialist Hospital & Research Centre), Ali Al Bshabshe(King Khalid University), Abdullah M. Assiri(King Khalid University), Frederick G. Hayden(University of Virginia Health System), Asim Alsaedi(King Saud bin Abdulaziz University for Health Sciences), Sarah Al Faraj(King Saud bin Abdulaziz University for Health Sciences), Hanan H. Balkhy(World Health Organization Regional Office for the Eastern Mediterranean), Abdulrahman Al Harthy(King Saud Medical City), Yasser Mandourah(Riyadh Armed Forces Hospital), Nisreen Murad Sherbeeni(Riyadh Armed Forces Hospital), Hani Jokhdar(Ministry of Health), Robert Fowler(Sunnybrook Health Science Centre), Ayed Y. Asiri(Prince Mohammed bin Abdulaziz Hospital), Sameera Aljohani, Mohammed Al Sulaiman(King Saud Medical City), Abdulaziz Al‐Dawood, Adel Alothman(King Saud bin Abdulaziz University for Health Sciences), Sameeh Ghazal(Prince Mohammed bin Abdulaziz Hospital), Ayman Kharaba(King Fahd Armed Forces Hospital), Majed Al Jeraisy(King Saud bin Abdulaziz University for Health Sciences), M. A. Abdelzaher(Cairo University), Suleiman Kojan(King Saud bin Abdulaziz University for Health Sciences)
Cited by 132
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k